StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell

StockNews.com lowered shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research note published on Wednesday morning.

Oramed Pharmaceuticals Trading Down 3.2 %

Shares of NASDAQ ORMP opened at $2.15 on Wednesday. The firm has a market cap of $86.67 million, a P/E ratio of 19.55 and a beta of 1.66. The business’s 50 day moving average is $2.33 and its 200-day moving average is $2.36. Oramed Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.67.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Murchinson Ltd. grew its stake in shares of Oramed Pharmaceuticals by 0.5% in the third quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after acquiring an additional 8,889 shares in the last quarter. XTX Topco Ltd grew its position in shares of Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares in the last quarter. Boothbay Fund Management LLC increased its holdings in shares of Oramed Pharmaceuticals by 2.0% during the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock worth $2,045,000 after purchasing an additional 16,857 shares during the period. World Equity Group Inc. acquired a new stake in shares of Oramed Pharmaceuticals in the fourth quarter valued at approximately $48,000. Finally, Marquette Asset Management LLC acquired a new stake in shares of Oramed Pharmaceuticals in the fourth quarter valued at approximately $81,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.